Role of Gliclazide in safely navigating type 2 diabetes mellitus patients towards euglycemia: Expert opinion from India

Q3 Medicine Endocrine and Metabolic Science Pub Date : 2021-09-30 DOI:10.1016/j.endmts.2021.100102

Subhash Wangnoo , M. Shunmugavelu , Sagili Vijaya Bhaskar Reddy , Vijay Negalur , Shreerang Godbole , Vinay K Dhandhania , Nareen Krishna , Kumar Gaurav

{"title":"Role of Gliclazide in safely navigating type 2 diabetes mellitus patients towards euglycemia: Expert opinion from India","authors":"Subhash Wangnoo , M. Shunmugavelu , Sagili Vijaya Bhaskar Reddy , Vijay Negalur , Shreerang Godbole , Vinay K Dhandhania , Nareen Krishna , Kumar Gaurav","doi":"10.1016/j.endmts.2021.100102","DOIUrl":null,"url":null,"abstract":"<div><p>Navigating safely towards euglycemia in type 2 diabetes mellitus (T2DM) is a real challenge in the current clinical practice despite availability of a number of glucose-lowering drugs; major barriers are hypoglycemia and weight gain. Sulfonylureas (SUs) have been recommended as one of the most common choice of add-on therapy to metformin (used as first line therapy). They are used extensively in Southeast Asia due to their high efficacy and low cost. However, there have been concerns regarding hypoglycemia, weight gain and cardiovascular safety with SUs. There is a need for an oral molecule that does not cause weight gain, has low risk of causing hypoglycemia, which can be used to navigate safely towards euglycemia with minimal constraints. Literature has shown that gliclazide provides consistent glycemic control with fewer hypoglycemic episodes and has long-term micro- and macrovascular benefits. This expert opinion was developed to highlight the role of SUs, and gliclazide in particular, in navigating effectively and safely towards the desired glycemic control in T2DM.</p></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.endmts.2021.100102","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine and Metabolic Science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266639612100025X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Navigating safely towards euglycemia in type 2 diabetes mellitus (T2DM) is a real challenge in the current clinical practice despite availability of a number of glucose-lowering drugs; major barriers are hypoglycemia and weight gain. Sulfonylureas (SUs) have been recommended as one of the most common choice of add-on therapy to metformin (used as first line therapy). They are used extensively in Southeast Asia due to their high efficacy and low cost. However, there have been concerns regarding hypoglycemia, weight gain and cardiovascular safety with SUs. There is a need for an oral molecule that does not cause weight gain, has low risk of causing hypoglycemia, which can be used to navigate safely towards euglycemia with minimal constraints. Literature has shown that gliclazide provides consistent glycemic control with fewer hypoglycemic episodes and has long-term micro- and macrovascular benefits. This expert opinion was developed to highlight the role of SUs, and gliclazide in particular, in navigating effectively and safely towards the desired glycemic control in T2DM.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

格列齐特在安全引导2型糖尿病患者走向正常血糖中的作用:来自印度的专家意见

在目前的临床实践中，尽管有许多降糖药物可用，但如何安全地引导2型糖尿病(T2DM)患者达到正常血糖是一个真正的挑战;主要障碍是低血糖和体重增加。磺脲类(SUs)已被推荐为二甲双胍(用作一线治疗)的最常见的附加治疗选择之一。由于其疗效高、成本低，在东南亚被广泛使用。然而，有关于低血糖、体重增加和心血管安全的担忧。需要一种口服分子，它不会导致体重增加，导致低血糖的风险低，可以在最小的限制下安全地引导到高血糖。文献表明，格列齐特提供持续的血糖控制，减少低血糖发作，并具有长期的微血管和大血管益处。这一专家意见的提出是为了强调SUs，特别是格列齐特在有效和安全地控制T2DM患者所需血糖方面的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊